Immunization, Hib3 in Israel
Israel: Immunization, Hib3 was 98.0% in 2024. ▲ Rising
Immunization, Hib3 in Israel, 1994–2024
Source: WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/). Measured in % of children ages 12-23 months.
Analysis
Israel recorded 98.0% for immunization, hib3 in 2024. That is the highest value across all 31 years on record.
Compared with earlier readings it is up 3.2% over ten years.
Over the whole period, immunization, hib3 in Israel peaked at 98.0% in 2017 and was at its lowest, 91.0%, in 2002.
Israel ranks 20th of 191 countries on this measure, in the top 10%.
The long-run direction has been consistently rising across the 31 years of available data.
Immunization, Hib3 in Israel, year by year
| Year | % of children ages 12-23 months | Change |
|---|---|---|
| 1994 | 92.0% | — |
| 1995 | 93.0% | +1.1% |
| 1996 | 92.0% | -1.1% |
| 1997 | 92.0% | +0.0% |
| 1998 | 94.0% | +2.2% |
| 1999 | 93.0% | -1.1% |
| 2000 | 93.0% | +0.0% |
| 2001 | 94.0% | +1.1% |
| 2002 | 91.0% | -3.2% |
| 2003 | 93.0% | +2.2% |
| 2004 | 95.0% | +2.2% |
| 2005 | 93.0% | -2.1% |
| 2006 | 94.0% | +1.1% |
| 2007 | 95.0% | +1.1% |
| 2008 | 94.0% | -1.1% |
| 2009 | 96.0% | +2.1% |
| 2010 | 95.0% | -1.0% |
| 2011 | 94.0% | -1.1% |
| 2012 | 94.0% | +0.0% |
| 2013 | 96.0% | +2.1% |
| 2014 | 95.0% | -1.0% |
| 2015 | 95.0% | +0.0% |
| 2016 | 94.0% | -1.1% |
| 2017 | 98.0% | +4.3% |
| 2018 | 98.0% | +0.0% |
| 2019 | 98.0% | +0.0% |
| 2020 | 98.0% | +0.0% |
| 2021 | 98.0% | +0.0% |
| 2022 | 98.0% | +0.0% |
| 2023 | 98.0% | +0.0% |
| 2024 | 98.0% | +0.0% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 1990s | 92.7% | 92.0% | 94.0% | 6 |
| 2000s | 93.8% | 91.0% | 96.0% | 10 |
| 2010s | 95.7% | 94.0% | 98.0% | 10 |
| 2020s | 98.0% | 98.0% | 98.0% | 5 |
Countries ranked near Israel
More health data for Israel
- Un projection of annual infant deaths, annual growth rate -1.65 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.6956 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 665.9 deaths per 1,000 people (2090)
- Number of infants who die before age 1 119 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2022)
- Population ages 00-04, female, annual growth rate -0.3823 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0445 units per person (2025)
- Population ages 00-04, male, annual growth rate -0.3508 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is immunization, hib3 in Israel?
- Immunization, hib3 in Israel was 98.0% in 2024, according to WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).
- What is the highest immunization, hib3 recorded in Israel?
- The highest recorded value was 98.0% in 2017.
- What is the lowest immunization, hib3 recorded in Israel?
- The lowest recorded value was 91.0% in 2002.
- How does Israel rank for immunization, hib3?
- Israel ranks 20th out of 191 countries with data for 2024.
- Is immunization, hib3 rising or falling in Israel?
- Over the last ten years it is up 3.2%. The long-run trend across the full record is rising.
- Where does this Israel data come from?
- The figures come from WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as part of Immunization, Hib3 (% of children ages 12-23 months). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 31 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.